Although antipsychotic treatment guidelines recommend routine metabolic screening, glucose and lipid profiles are not routinely being ordered at baseline by prescribing physicians in a patient population already at risk for diabetes and cardiovascular disease.
The purpose of the study was to evaluate the impact of abnormal laboratory test results on the selection of atypical antipsychotic treatment for patients whose lipids and fasting blood glucose (FBG) were being measured.
READ MORE @ DOCTOR'S GUIDE
Monday, May 28, 2007
Subscribe to:
Posts (Atom)
